-
The REduction of Atherothrombosis for Continued Health (REACH) study is an international registry of patients on antithrombic therapy that provides an opportunity to evaluate the risk of ischemic and bleeding outcomes in patients with coronary artery disease (CAD).
-
-
A new product has been approved for the urgent reversal of warfarin or other vitamin K antagonists anticoagulation in the setting of acute bleeding. This human plasma-derived product contains vitamin K-dependent coagulation Factors II, VII, IX, and X as well as antithrombotic Protein C and Protein S. It is heat-treated and viral filtered. Prothrombin complex concentrate (PCC) is manufactured by CSL Behring GmbH in Germany and marketed by CSL Behring LLC as Kcentra. The product has been licensed in Germany since 1996.
-
Optimism is associated with a significantly healthier lipid profile than is present in less optimistic persons, possibly due to healthier behaviors and lower body mass indices, which are found with increased frequency in optimistic individuals.
-
More than 95% of shoulder dislocations are anterior in location.
Pre- and post-reduction radiographs are not required in patients with chronic recurrent dislocations who have dislocations with minor or no trauma.
Leverage reduction techniques may be able to reduce the dislocation without the need for opiates or sedatives.
Post-reduction immobilization is primarily done for patient comfort, not to reduce the risk of recurrent dislocation.
-
-
Among deployed U.S. service members who died of combat or unintentional injuries and received autopsies, the prevalence of atherosclerosis varied by age and cardiovascular risk factors.
-
-
Adults with private health care insurance in the United States have suboptimal testing for chronic hepatitis B virus (HBV) and hepatitis C virus (HCV). Clearly, increased awareness is needed regarding HBV and HCV infections, epidemiology, risk, and screening.
-
The authors concluded that in patients with AF, decreasing GFR was associated with a higher risk of cardiovascular events and bleeding. Apixaban as compared to warfarin reduced these risks regardless of renal function, with the greatest benefit seen in reducing major bleeding in those with impaired renal function.